Search Results 261-270 of 17494 for Vitiligo

1. A Study of Pembrolizumab Alone or Combined with CC-486 for Patients with Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer - Mayo Clinic

   Vitiligo or resolved childhood asthma/atopy will not be excluded. Received live vaccines within 30 days prior to enrollment; Current or prior history of ...

2. Skin biopsy - Doctors & Departments - Mayo Clinic

   Vitiligo. Show more related content. Products & Services. A Book: Mayo Clinic Family Health Book · Newsletter: Mayo Clinic Health Letter — Digital Edition. Show ...

3. A Study to Determine the Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies - Mayo Clinic

   NOTE: Subjects with vitiligo, Grave's disease not requiring systemic treatment other than thyroid hormone replacement (within the past 2 years), or ...

4. Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas - Mayo Clinic

   Subjects with vitiligo or resolved childhood asthma/atopy would be an exception to this rule. Evidence of interstitial lung disease or active, non ...

5. Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma - Mayo Clinic

   Active, known or suspected autoimmune disease other than patients with vitiligo, residual hypothyroidism only requiring hormone replacement, psoriasis not ...

6. A Safety Study of SEA-TGT (SGN-TGT) in Patients With Advanced Cancer - Mayo Clinic

   colitis, pneumonitis, transaminitis); Participants with vitiligo, controlled type 1 diabetes mellitus, residual hypothyroidism requiring hormone replacement ...

7. Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma - Mayo Clinic

   Note: Vitiligo, type 1 diabetes mellitus, residual hypothyroidism due to autoimmune thyroiditis only requiring hormone replacement, and conditions ...

8. A Study to Evaluate M7824 with Concurrent Chemoradiation (cCRT) in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) - Mayo Clinic

   Participants with diabetes Type I, vitiligo, alopecia, psoriasis, hypo- or hyperthyroid disease not requiring immunosuppressive treatment are eligible.

9. Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas - Mayo Clinic

   Subjects are permitted to enroll if they have vitiligo, resolved childhood asthma/atopy, type I diabetes mellitus, residual hypothyroidism due to autoimmune ...

10. A Study to Test the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) with One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors - Mayo Clinic

    Patients with vitiligo, endocrine deficiencies including thyroiditis managed with replacement hormones or medications (eg thyrodidits managed with PTU or ...